Aclaris Therapeutics develops prescription drug candidates, testing them in clinical trials and planning to sell approved products through partners. ACRS reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 1 | Canaccord Genuity | Initiated | Buy | |
| Jun 2 | LifeSci Capital | Initiated | Buy | |
| May 5 | Guggenheim | Initiated | Buy | |
| Apr 16 | Oppenheimer | Initiated | Buy |
Seasonality
How ACRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options Flow
90DNo whale options trades in ACRS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACRS is in one of them and how their past ACRS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ACRS in an article yet. Here's the latest on the wider market.
About Aclaris Therapeutics
Aclaris Therapeutics is a pharmaceutical company based in Wayne, Pennsylvania. It develops prescription drug product candidates and tests them in clinical trials, relying on outside research organizations to run much of that work. The company plans to bring approved products to patients through outside partners, who would sell them to patients, insurers and government health programs. It also depends on outside suppliers to manufacture the drug supplies used in its trials.
- Headquarters
- Wayne, PA